PRIVIA HEALTH GROUP INC (PRVA)
Health Care · healthcare services / value-based care platform · NASDAQ
Privia Health is a technology-enabled physician enablement company that empowers providers to succeed in value-based care through its cloud-based platform and clinical support.
What PRIVIA HEALTH GROUP INC does
Privia Health Group, Inc. is a healthcare platform company that partners with medical groups, health plans, and health systems to facilitate the transition to value-based care. The company provides a proprietary, cloud-based technology solution and clinical services aimed at optimizing physician practices, improving patient outcomes, and reducing the total cost of care.
Themes: value-based care, physician enablement, healthcare technology, digital health
Fundamentals
- Price$22.93 as of 2026-10-20 close
- Market cap$2.9B as of 2026-07-31 (share count; price 2026-10-20)
- 1-year return-13.1% 2025-10-20 close $26.40 → 2026-10-20 close $22.93
- P/E104.23 as of 2026-10-20
- ROE+2.9% FY2025, SEC XBRL
- ROICn/a No figure: its filing tags none of the debt lines we read, which is not evidence of zero debt.
- Debt / equityn/a No figure: its filing tags none of the debt lines we read, which is not evidence of zero debt.
- Beta0.65 as of 2026-09-02
- Last reported earnings2026-08-06 SEC EDGAR Form 8-K (Item 2.02)
How PRVA compares in its sector
- price-to-earnings ratiotop 10% 181 covered Health Care peers, as of 2026-10-20
- return on equitymiddle range 510 covered Health Care peers, as of 2026-09-02
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
Quarterly results
| Quarter | Operating income | Net income | Diluted EPS | Operating cash flow |
|---|---|---|---|---|
| Q2 FY2026 2026-06-30 | $12M | $9M | $0.07 | $1M† |
| Q1 FY2026 2026-03-31 | $7M | $3M | $0.02 | -$49M |
| Q4 FY2025 2025-12-31 | $11M† | $9M† | $0.07† | $128M† |
| Q3 FY2025 2025-09-30 | $14M | $7M | $0.05 | $52M† |
| Q2 FY2025 2025-06-30 | $3M | $3M | $0.02 | $8M† |
| Q1 FY2025 2025-03-31 | $5M | $4M | $0.03 | -$24M |
| Q4 FY2024 2024-12-31 | $5M† | $4M† | $0.03† | $75M† |
| Q3 FY2024 2024-09-30 | $6M | $4M | $0.03 | $33M† |
† Not filed as a discrete quarter: derived from the company's own year-to-date figures (for example the fourth quarter as the fiscal year minus the first nine months). A derived per-share figure is approximate, because the share count moves within the year.
Balance sheet at 2026-06-30
- Cash and equivalents$412M
- Total debtnot shown the filing tags none of the debt lines we read — not evidence of zero debt
From the company's own SEC 10-Q and 10-K filings (XBRL), re-read every week. Figures in US dollars as filed; informational only — not financial advice.
How PRIVIA HEALTH GROUP INC looks technically
PRIVIA HEALTH GROUP INC (PRVA) is trading 0.7% above its 200-day average, the long-term trend line — a longer-term uptrend. Its 50-day average crossed below its 200-day average about 25 trading days ago — a "death cross", a bearish long-term signal. A strong uptrend is in place — ADX, a 0–100 trend-strength gauge, is 29, with buyers in control. Momentum is stretched — its 14-day RSI (a 0–100 momentum gauge) is 74, in overbought territory (above 70). It just made a new 20-day high, its first since 2026-08-05, pushing above its recent trading range. It is 20.4% below its highest point of the past year.
Trend
8
| Distance from the 200-day | it is trading 0.7% above its 200-day average, the long-term trend line — a longer-term uptrend | +0.7% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $20.80 | $20.80 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $22.76 | $22.76 |
| Swing structure | each recent peak has been lower than the one before it and each dip deeper — the pattern chart-watchers call a downtrend, which describes where price has already been and not where it goes next | lower highs and lower lows |
| Last swing turn | its last significant turn was a swing low 26 calendar days ago — the swings before that are what the structure reading is measured on | 26 sessions |
| Since the 50/200 cross | its 50-day average crossed below its 200-day average about 25 trading days ago — a "death cross", a bearish long-term signal | 25 sessions |
| Above the 200-day after a dip | it recently dipped to its 200-day average (the long-term trend line) and has since climbed back above it — now about 0.7% above | +0.7% |
| Trend strength (14-day ADX) | a strong uptrend is in place — ADX, a 0–100 trend-strength gauge, is 29, with buyers in control | 29.4 |
Momentum
3
| 14-day RSI | momentum is stretched — its 14-day RSI (a 0–100 momentum gauge) is 74, in overbought territory (above 70) | 74.4 |
|---|---|---|
| Position in its 14-day range | it is trading near the top of its 14-day range ($19.49 to $23.13) — its "stochastic" reading is 95 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been climbing within that range over the last few sessions. | 94.5 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, is in positive territory (momentum leaning bullish) | 18 sessions |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $28.82 | $28.82 |
|---|---|---|
| From the 52-week high | it is 20.4% below its 52-week high (its highest price of the past year) | -20.4% |
| Above the 52-week low | it is 21.2% above its 52-week low (its lowest price of the past year) | +21.2% |
| Below the 52-week high | it is 20.4% below its highest point of the past year | 20.4% |
| Since a 20-day breakout | it just made a new 20-day high, its first since 2026-08-05, pushing above its recent trading range | 1 session |
| Since a 55-day breakout | it made a new 55-day low about 20 trading days ago | 20 sessions |
| All-time high | its highest closing price on record is $34.89 (set on 2022-10-18) | $34.89 |
| Given back of the 52-week move | over the past year its closes ranged ($19.10 to $28.10), and it has recovered roughly a third of its fall from last year’s high — 43% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $24.66 to $24.95. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 42.6% |
| From the all-time high | it is 34.3% below its all-time high | -34.3% |
| Nearest price level | it is trading 0.8% below a resistance level at $23.11 — a price it turned at four times since 2024-11-13, most recently on 2025-12-17. Since 2024-10-21 it has 7 such levels below the current price and 6 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | +0.8% |
| All-time low | its lowest closing price on record is $15.92 (set on 2024-05-21) | $15.92 |
| Above the all-time low | it is 44.0% above its all-time low | +44.0% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are about average versus its own recent 6-month history | 70th percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $0.6289 between its high and its low — about 2.7% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $0.6289 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $18.44 and $23.07 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $18.44 – $20.75 – $23.07 |
| Typical daily range (% of price) | its price moves about 2.7% in a typical session — calmer than most companies we cover. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 2.7% |
| Stretch from the 200-day average | it is trading 0.3 daily ranges above its 200-day average price (0.7% above it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 0.3 daily ranges above its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is about normal versus its 30-day average | 0.61× |
|---|
Analyst
2
| Change in the average price target | analysts' average price target is unchanged from the prior reading | 0.0% |
|---|---|---|
| Change in the consensus rating | the analyst consensus rating is unchanged since the prior reading | unchanged |
Price gaps
2
| Gap at the open | it opened on 2026-10-20 0.9% above the previous session's close — an overnight gap, the part of the move that happened while the market was shut, and had not traded back through that level by the close | +0.9% |
|---|---|---|
| Open gap | it gapped 12.8% below the previous close 52 sessions ago and has not traded back through the level it left behind at 23.96 — an "unfilled gap", which describes a price range no trade has since crossed and is not a forecast that it will be crossed | -12.8% |
Price streaks
1
| Closing streak | it closed higher in its latest session, after a session that did not close higher — a single up day rather than a run | 1 session up |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock beat the market by 14.6 percentage points (the stock gained 15.5% while the market gained 1.0%) | +14.6% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock lagged the market by 16.3 percentage points (the stock lost 12.7% while the market gained 3.6%) | -16.3% |
| vs market, 6 months | over the past 6 months this stock lagged the market by 13.3 percentage points (the stock lost 4.8% while the market gained 8.5%) | -13.3% |
| vs market, 12 months | over the past 12 months this stock lagged the market by 27.7 percentage points (the stock lost 13.1% while the market gained 14.6%) | -27.7% |
Signal agreement
2
| Bullish technical signals | 4 of the 9 technical signals we can compute for it are currently in a bullish state: trading above its 200-day average, a fresh 20-day high, MACD momentum is positive, a strong uptrend, with buyers in control — these describe past price behaviour, not a forecast | 4 of 9 |
|---|---|---|
| Bearish technical signals | 4 of the 9 technical signals we can compute for it are currently in a bearish state: a "death cross" — its 50-day average is below its 200-day, its RSI momentum gauge is overbought (a stretched reading), lagging the market over 6 months, near the top of its 14-day range (overbought) — these describe past price behaviour, not a forecast | 4 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading inside the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-09-14 and projected forward over today's price, the zone traders read as unresolved — neither side has established a trend, and the band is where that gets settled. The band itself is thick, spanning 13.6% of the share price, which is taken to mean a barrier that has held for a while and takes effort to cross. | 0.0% |
|---|
Volume-weighted price
2
| Vs this year’s average price paid | the price is 1% above the average price paid so far this year, so the typical buyer over that stretch is showing a gain. That average is $22.79 — a volume-weighted average of daily closes over 196 sessions, not a true tick-by-tick VWAP. | +0.6% |
|---|---|---|
| Vs the average paid since it last reported | the price is 10% above the average price paid since it last reported on 2026-08-06 (its 10-Q), so the typical buyer over that stretch is showing a gain. That average is $20.92 — a volume-weighted average of daily closes over 53 sessions, not a true tick-by-tick VWAP. | +9.6% |
Price levels it has turned at before
PRVA last closed at $22.93 on 2026-10-20. Since 2024-10-21 it has turned at 7 prices below its last close and 6 above; the 3 nearest below and the 3 nearest above are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $23.11 | Resistance | 0.8% above the last close | turned there four times · 2024-11-13 to 2025-12-17 |
| $22.59 | Support | 1.5% below the last close | turned there five times · 2024-11-25 to 2026-02-17 |
| $22.16 | Support | 3.4% below the last close | turned there five times · 2024-12-16 to 2025-11-19 |
| $23.79 | Resistance | 3.7% above the last close | turned there 7 times · 2025-01-22 to 2026-05-19 |
| $24.22 | Resistance | 5.6% above the last close | turned there twice · 2025-03-25 to 2026-01-26 |
| $21.43 | Support | 6.5% below the last close | turned there three times · 2025-06-23 to 2026-09-08 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
No Elliott-wave labelling currently fits its swings: the recent highs and lows do not satisfy the three rules a five-wave count has to obey, so there is no count to show rather than a count we are unsure about.
Read from daily closes as of 2026-10-20.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Near 200-day moving-average support · Trading above the 200-day moving average · Trading above the 50-day moving average · Recent death cross (50-day crossed below 200-day) · Overbought (14-day RSI above 70) · Pulled back from the 12-month high | Learn: moving average · golden cross · adx · rsi · breakout · fifty two week high low
Based on daily closing prices as of 2026-10-20. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Consensus ratingStrong Buy (1.39 mean, 1=Strong Buy…5=Strong Sell) — 17 analysts
- Mean price target$31.47 range $24.00 – $40.00; median $31.00
Analyst estimates, as of 2026-10-18. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for PRVA
- Consensus EPS estimate$0.238 next reporting period, as of 2026-10-18
- Estimate change, 30 days-$0.00317 (-1.3%) from $0.2412, on 2026-09-13, 35-day window
- Readings revised upward11% of 9 comparable readings
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["Heavily regulated environment subject to frequent changes in healthcare laws and reimbursement rates.","Dependence on third-party electronic medical record (EMR) vendor, athenahealth, Inc.","Risks associated with the integration and growth strategy of new medical groups and geographic markets."]
What changed in the latest 10-Q
AI-assisted comparison of PRVA's 10-Q filed 2026-05-07 against the prior one filed 2025-11-06.
Management's Discussion & Analysis (MD&A)
- Added:
- Newer filing adds specific description: 'Our technology and service solutions (collectively, the "Privia Platform") are powered by our Privia Technology Solution that integrates both Privia-developed and third-party applications into a seamless interface and workflow that manages all aspects of our Privia Providers' provision of healthcare services.'
- Newer filing adds language about MSO services: 'We provide management services to the Medical Groups through a local MSO, which provides Medical Groups with access to VBC opportunities either directly or through Privia-owned Accountable Care Organizations ("ACOs").'
- Newer filing adds: 'Summary of Key Metrics and Non-GAAP Financial Measures' as a section heading before the metrics table
- Newer filing reports Q1 2026 comparative financial metrics (March 31, 2026 vs March 31, 2025)
- Newer filing updates reconciliation language: 'for reconciliations of these key metrics and non-GAAP financial measures to the most comparable GAAP measures, including gross profit to Care Margin, gross profit to Platform Contributor, and net income to Adjusted EBITDA.'
- Removed:
- Older filing contains Q3 2025 comparative metrics (September 30, 2025 vs September 30, 2024) and nine-month period data; newer filing removes all September 30 period references
- Older filing references 'virtual scribes' in other revenue services description; newer filing removes this reference
- Older filing states 'We provide management and administrative services' to Medical Groups; newer filing states only 'We provide management services'
- Older filing states ACO access through 'a Privia-owned ACO'; newer filing states 'Privia-owned Accountable Care Organizations ("ACOs")'
- Older filing states 'we furnish population health services, reporting and analytics, along with certain management services'; newer filing adds 'along with certain management' without 'services' at end of phrase
- Older filing references 'for a reconciliation' (singular); newer filing references 'for reconciliations' (plural)
- Reworded:
- Older: 'management and administrative services'; Newer: 'management services' (removal of 'and administrative')
- Older: 'through a Privia-owned ACO'; Newer: 'through Privia-owned Accountable Care Organizations ("ACOs")' (expansion and formalization)
- Older: 'management services' at end of Care Partners description; Newer: 'certain management' (less explicit about services)
- Notes:
- The newer filing is a Q1 2026 10-Q (quarter ended March 31, 2026) while the older filing is a Q3 2025 10-Q (quarter ended September 30, 2025), representing different reporting periods with different financial metrics
- The MD&A section appears to be truncated in both filings, ending mid-sentence in the VBC Revenue section
- Some wording differences may reflect natural evolution of disclosure language rather than substantive business changes
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
No open-market insider purchases or sales recorded in the last 90 days, of which we have read Form 4 filings through 2026-10-16. The 5 days since 2026-10-16 have not been checked yet.
- Last 180 days · read to 2026-10-160 buys · 18 sells ($16M) — 3 selling insiders
Most recent open-market transaction: 2026-07-09. Based on Form 4 filings read through 2026-10-16; anything filed since is not yet included.
View full insider trading history → View SEC Form 3/4/5 filingsAsk about PRVA's insider activity →
Only open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Institutional ownership (13F)
5 institutional 13F filers reported holding PRVA as of 2026-06-30 (quarter-end position, filed within 45 days).
- Distinct 13F filers 5
- Reported shares held 39,943,613
- Reported value $1,027,749,158
reported quarterly holdings change (2026-03-31 → 2026-06-30): 0 new, 2 increased, 3 decreased, 1 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Ask about PRVA's institutional holders → See what each manager we track holds →
Short interest (FINRA)
PRVA had 5,807,295 shares of reported short interest as of the 2026-09-30 FINRA settlement date (delayed, bi-monthly; not real-time).
PRVA had 4.55% of its shares outstanding sold short as of the 2026-09-30 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 4.31 days to cover at the same settlement.
- Reported short interest (shares) 5,807,295
- Short interest (% of shares outstanding) 4.55%
- Prior settlement (shares) 4,900,411
- Reported change 18.51%
- Days to cover (reported) 4.31
Reported to FINRA as of the 2026-09-30 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
PRIVIA HEALTH GROUP INC is found in…
Frequently asked questions
What does PRIVIA HEALTH GROUP INC (PRVA) do?
Privia Health Group, Inc. is a healthcare platform company that partners with medical groups, health plans, and health systems to facilitate the transition to value-based care. The company provides a proprietary, cloud-based technology solution and clinical services aimed at optimizing physician practices, improving patient outcomes, and reducing the total cost of care.
What sector is PRIVIA HEALTH GROUP INC (PRVA) in?
PRIVIA HEALTH GROUP INC (PRVA) is classified in the Health Care sector. Its industry is healthcare services / value-based care platform. It trades on NASDAQ.
Is PRIVIA HEALTH GROUP INC (PRVA) overbought or oversold right now?
PRIVIA HEALTH GROUP INC (PRVA) is currently in overbought territory (its 14-day RSI is 74, above 70) (as of 2026-10-20). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on PRVA come from?
Fundamentals come from SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-02 for the rest; prices are market data, as of 2026-09-02; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-02 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-20.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.